News
Featured News
Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.
BIOVECTRA partners on Canadian solution to establish a domestic supply chain for immunotherapies
February 26, 2024
PhaseBio Pharmaceuticals and BIOVECTRA Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
MALVERN Pa 038 SAN DIEGO 8212 PhaseBio Pharmaceuticals Inc Nasdaq PHAS a clinical stage biopharmaceutical company 8230
<a class= btn btn secondary understrap
Major investment anchors alliance for bioscience skills and training in Atlantic Canada
Charlottetown PE Today the Future Skills Centre FSC announced the investment of $1 5 million to support the establishment of the Canadian Alliance for Skills
COVID-19: Our Obligation
At BioVectra we take our obligation as an essential service very seriously 8230
<a class= btn btn secondary understrap read more link
Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation
Much of the innovation occurring in the pharmaceutical industry today is achieved by smaller pharma biotech firms with limited commercial manufacturing experience 8230
BIOVECTRA Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital
BioVectra Inc excited for continued growth under experienced CDMO investor H I G Capital 8230
<a class= btn btn secondary understrap read more
Mallinckrodt Agrees to Sell BIOVECTRA Inc. to H.I.G. Capital for $250 Million
Statement from BIOVECTRA President, Oliver Technow, on BIOVECTRA’s sale to H.I.G. Capital: “We are very excited to enter into this new chapter with H.I.G. Capital! […]